Market Overview

UPDATE: Jefferies Raises PT on Becton, Dickinson and Co. on Compelling Secular Growth Story

Related BDX
Morgan Stanley Sees Execution Priced In For Becton, Dickinson and Co.
Becton, Dickinson Unveils Blood Culture Instrument Connectivity - Analyst Blog

In a report published Thursday, Jefferies analyst Jon Wood reiterated a Buy rating on Becton, Dickinson and Co. (NYSE: BDX), and raised the price target from $96.00 to $107.00.

In the report, Wood noted, “BDX's foray into the generic prefilled injectable drug arena adds a new compelling secular growth story to the investment thesis. With its main competitor enduring chronic manufacturing / QC issues, BDX's ability to leverage its hospital channel presence should help stimulate initial uptake. We are raising our FY14 EPS forecast to $6.25 (from $6.20). Our PT moves to $107 (from $96) on higher intermediate-term cash flow forecasts.”

Becton, Dickinson and Co. closed on Wednesday at $95.16.

Posted-In: JefferiesAnalyst Color Price Target Analyst Ratings

 

Most Popular

Related Articles (BDX)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free